Article

Authors’ Reply: New Information on Asymptomatic Pre-excitation

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Dear Sir,

We appreciate the interest of Dr Eleftherios Giozitzoglou in our work.1 In the first retrospective registry,2 in which more than 300,000 individuals had an ECG over a period of 11 years (29 % of total population), a separate analysis of asymptomatic subjects and sudden cardiac death was not addressed in the group of 310 subjects with ventricular pre-excitation. However, and interestingly, ventricular pre-excitation was associated with an increased morbidity related to increased risk of AF (HR 3.12, 95 % CI [2.07–4.70]) and heart failure (HF) (HR 2.11, 95 % CI [1.27–3.50]). The risk of AF persisted even after performing catheter ablation. The higher risk of HF was associated in particular with the anteroseptal localisation, with tachycardiomyopathy or dyssynchrony as the potential mechanism. Although there was no significant difference between subjects with and without pre-excitation in the entire population, total mortality was significantly higher in those ≥65 years of age (HR 1.85, 95 % CI [1.07–3.18]). The poorly tolerated supraventricular tachycardias among individuals with pre-excitation ≥60 years and the increased burden of AF could explain this finding. The anteroseptal localisation was associated with a borderline statistically significant higher risk of total mortality (HR 2.4, 95 % CI [0.96–4.77]) and the higher risk of HF with this localisation could be the reason for that.

The second multicentre retrospective observational study in a paediatric population (≤21 years of age),3 published subsequent to our review, showed a high incidence of life-threatening events (49 % of rapidly conducted pre-excited AF, 45 % of aborted sudden death and 6 % of sudden death) and in 40 % of these cases as a first manifestation of the disease. But, more importantly, 36 % of evaluated cases had a shortest pre-excited RR interval (SPERRI) >250, 37 % did not have concerning pathway characteristics and 25 % had neither concerning pathway characteristics nor inducible atrioventricular reciprocant tachycardia.

Consequently, and according to these data, catheter ablation could be considered as a better strategy than follow-up in all asymptomatic subjects to reduce the known risk of sudden cardiac death regardless of the anterograde conduction properties. Despite ventricular pre-excitation being a risk factor for HF, total mortality needs to be confirmed in future studies. Available data so far reinforce the role of catheter ablation in decreasing morbidity and mortality in this group of patients.

References

  1. Brugada J, Keegan R. Asymptomatic ventricular pre-excitation: between sudden cardiac death and catheter ablation. Arrhyth & Electrophysiol Rev 2018;7:32–8.
    Crossref | PubMed
  2. Skov MW, Rasmussen PV, Ghouse J, et al. Electrocardiographic preexcitation and risk of cardiovascular morbidity and mortality: results from the Copenhagen ECG study. Circ Arrhythm Electrophysiol 2017;10:pii,e004778.
    Crossref | PubMed
  3. Etheridge SP, Escudero CA, Blaufox AD, et al. Life-threatening event risk in children with Wolff–Parkinson–White syndrome. JACC: Clin Electrophysiol 2018;4:433–44.
    Crossref